Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 9/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.49 |
| ▸ | MEN1 | O00255 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7415910 | 0.87 | JAK2 (0.48) | SIRT6MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL8302020 | 0.85 | DTYMK (0.48) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL6774142 | 0.83 | MAPT (0.51) | MAPTALDH1A1LMNAL3MBTL1RXFP1 | |
| SCHEMBL7827654 | 0.81 | SIRT6 (0.63) | SIRT6MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL23292639 | 0.80 | MAPT (0.48) | MAPTALDH1A1KMT2ALMNANPSR1 | |
| SCHEMBL3369502 | 0.80 | MAPT (0.48) | MAPTALDH1A1LMNARXFP1KDM4E | |
| SCHEMBL18094315 | 0.80 | MAPT (0.48) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL3364708 | 0.80 | MAPT (0.48) | MAPTALDH1A1LMNARXFP1KDM4E | |
| SCHEMBL20556372 | 0.78 | MAPT (0.52) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL29495258 | 0.78 | MAPT (0.61) | SIRT6MAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2010037059-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010037059-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | SIRT6 2447/4885MAPT 4858/4885ALDH1A1 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.